Abstract
Colorectal cancer has the highest incidence rate in the Czech Republic and occupies one of the leading positions in incidence worldwide. Only patients with resectable distant metastases have hope for a cure.
Prolongation of survival and improvement in the quality of life thus remain the main goal of cancer treatment. The possibilities of classic chemotherapy appear to be currently exhausted.
Further prolongation of survival of patients with metastatic colorectal cancer (mCRC) has been provided by targeted biological therapy. It is crucial to find suitable predictive biomarkers that will allow identification of a target population of patients.
The review article analyses the RAS mutation status with respect to the possible sequence of targeted biological therapy in patients with mCRC.